Literature DB >> 6605800

Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course. II. Evaluation of 69 patients with lung carcinoma.

F Vánky, A Péterffy, K Böök, J Willems, E Klein, G Klein.   

Abstract

T-cell-enriched lymphocyte populations of 69 lung carcinoma (44 squamous cell, 23 adeno-, and two large cell carcinoma) patients were investigated at the time of surgery for proliferative response to, and/or cytotoxic potential against, freshly separated autologous tumor cells. Tumor-free period and survival time of the patients were correlated with the reactivity obtained in the in vitro tests. The observation time varied between 20 and 78 months (mean 52). Tumor-free period and survival time were longer and survival rate higher in the group with lymphocyte reactivity toward their tumors. In the non-reactive group, all patients but one died within 3 years. Almost all patients had cytotoxic lymphocytes against K562, the three who did not belonging to the category with short survival time.

Entities:  

Mesh:

Year:  1983        PMID: 6605800     DOI: 10.1007/bf00199900

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer.

Authors:  M J Matthews; S Kanhouwa; J Pickren; D Robinette
Journal:  Cancer Chemother Rep 3       Date:  1973-03

2.  Study of the tumor cell-lymphocyte interaction in patients with breast cancer.

Authors:  S D Deodhar; G Crile; C B Esselstyn
Journal:  Cancer       Date:  1972-05       Impact factor: 6.860

3.  Human tumor-lymphocyte interaction in vitro. III. T lymphocytes in autologous tumor stimulation (ATS).

Authors:  F Vánky; E Klein; J Stjernswärd; L Rodriguez; A Péterffy; L Steiner; U Nilsonne
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

4.  Evaluation of the long-term results of surgery for bronchial carcinoma.

Authors:  R A Smith
Journal:  J Thorac Cardiovasc Surg       Date:  1981-09       Impact factor: 5.209

5.  Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity.

Authors:  F T Vánky; B M Vose; M Fopp; E Klein
Journal:  J Natl Cancer Inst       Date:  1979-06       Impact factor: 13.506

6.  Long-term survival and cure in lung cancer surgery.

Authors:  H R Sørensen
Journal:  Thorac Cardiovasc Surg       Date:  1982-10       Impact factor: 1.827

7.  Restricted autologous lymphocytotoxicity in lung neoplasia.

Authors:  B M Vose; F Vánky; M Fopp; E Klein
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

8.  Specific and non-specific lymphocyte cytotoxicity in colon carcinoma.

Authors:  B M Vose; P Gallagher; M Moore; P F Schofield
Journal:  Br J Cancer       Date:  1981-12       Impact factor: 7.640

  8 in total
  18 in total

1.  Cytotoxic and noncytotoxic mechanisms involved in the in vitro anti-leukaemia effects of T cell clones established from a chronic myelogenous leukaemia patient during treatment in vivo with interferon alpha.

Authors:  G Pawelec; M Reutter; M Owsianowsky; A Rehbein; F W Busch
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.

Authors:  P Allavena; P Lo Presti; M Di Bello; V Lucchini; A Lissoni; G Zanetta; C Mangioni; A Mantovani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 3.  Biological significance of autologous tumor-killing activity and its induction therapy.

Authors:  A Uchida
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

4.  The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells.

Authors:  F Vánky; P Wang; E Klein
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Tumour volume and macroscopic growth pattern of bronchogenic carcinoma.

Authors:  K Kayser; H Toomes; H H Vollhaber; H U Burkhardt
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

Review 6.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Activated T-cell subsets in benign lymphoid hyperplasias and B-cell non-Hodgkin's lymphomas.

Authors:  J I Diaz; M G Edinger; M H Stoler; R R Tubbs
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

8.  DR antigens expressed on tumor cells do not contribute to the blastogenetic response of autologous T cells.

Authors:  F Vánky; E Klein; J Willems
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study.

Authors:  A Balsari; R Marolda; C Gambacorti-Passerini; G Sciorelli; G Tona; E Cosulich; D Taramelli; G Fossati; G Parmiani; N Cascinelli
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  In vitro generation of tumour-specific lymphocyte reactivity to colonic carcinoma cells. Comparison with normal colonic mucosa cells.

Authors:  M Kuppner; S Wilkinson; E Casson; O Eremin
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.